SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
QQQ   268.56 (-4.00%)
AAPL   140.05 (-3.70%)
MSFT   233.79 (-5.27%)
META   133.21 (-4.21%)
GOOGL   98.53 (-2.85%)
AMZN   114.31 (-4.98%)
TSLA   222.41 (-6.60%)
NVDA   120.46 (-8.26%)
NIO   13.75 (-6.91%)
BABA   81.42 (-3.44%)
AMD   58.40 (-13.93%)
T   14.97 (-2.28%)
MU   52.90 (-3.15%)
CGC   2.81 (-25.07%)
F   12.22 (-1.13%)
GE   64.57 (-2.49%)
DIS   97.18 (-2.86%)
AMC   6.53 (-8.29%)
PYPL   90.16 (-4.51%)
PFE   42.22 (-2.02%)
NFLX   225.33 (-6.12%)
QQQ   268.56 (-4.00%)
AAPL   140.05 (-3.70%)
MSFT   233.79 (-5.27%)
META   133.21 (-4.21%)
GOOGL   98.53 (-2.85%)
AMZN   114.31 (-4.98%)
TSLA   222.41 (-6.60%)
NVDA   120.46 (-8.26%)
NIO   13.75 (-6.91%)
BABA   81.42 (-3.44%)
AMD   58.40 (-13.93%)
T   14.97 (-2.28%)
MU   52.90 (-3.15%)
CGC   2.81 (-25.07%)
F   12.22 (-1.13%)
GE   64.57 (-2.49%)
DIS   97.18 (-2.86%)
AMC   6.53 (-8.29%)
PYPL   90.16 (-4.51%)
PFE   42.22 (-2.02%)
NFLX   225.33 (-6.12%)
QQQ   268.56 (-4.00%)
AAPL   140.05 (-3.70%)
MSFT   233.79 (-5.27%)
META   133.21 (-4.21%)
GOOGL   98.53 (-2.85%)
AMZN   114.31 (-4.98%)
TSLA   222.41 (-6.60%)
NVDA   120.46 (-8.26%)
NIO   13.75 (-6.91%)
BABA   81.42 (-3.44%)
AMD   58.40 (-13.93%)
T   14.97 (-2.28%)
MU   52.90 (-3.15%)
CGC   2.81 (-25.07%)
F   12.22 (-1.13%)
GE   64.57 (-2.49%)
DIS   97.18 (-2.86%)
AMC   6.53 (-8.29%)
PYPL   90.16 (-4.51%)
PFE   42.22 (-2.02%)
NFLX   225.33 (-6.12%)
QQQ   268.56 (-4.00%)
AAPL   140.05 (-3.70%)
MSFT   233.79 (-5.27%)
META   133.21 (-4.21%)
GOOGL   98.53 (-2.85%)
AMZN   114.31 (-4.98%)
TSLA   222.41 (-6.60%)
NVDA   120.46 (-8.26%)
NIO   13.75 (-6.91%)
BABA   81.42 (-3.44%)
AMD   58.40 (-13.93%)
T   14.97 (-2.28%)
MU   52.90 (-3.15%)
CGC   2.81 (-25.07%)
F   12.22 (-1.13%)
GE   64.57 (-2.49%)
DIS   97.18 (-2.86%)
AMC   6.53 (-8.29%)
PYPL   90.16 (-4.51%)
PFE   42.22 (-2.02%)
NFLX   225.33 (-6.12%)
NASDAQ:AMED

Amedisys - AMED Stock Forecast, Price & News

$94.46
-2.70 (-2.78%)
(As of 10/7/2022 03:58 PM ET)
Add
Compare
Today's Range
$93.76
$97.11
50-Day Range
$96.79
$127.87
52-Week Range
$95.33
$188.88
Volume
13,443 shs
Average Volume
376,692 shs
Market Capitalization
$3.06 billion
P/E Ratio
22.02
Dividend Yield
N/A
Price Target
$153.13

Amedisys MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.53 Rating Score
Upside/​Downside
60.7% Upside
$153.13 Price Target
Short Interest
Bearish
6.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.06mentions of Amedisys in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.26%
From $5.33 to $5.93 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

187th out of 1,075 stocks

Home Health Care Services Industry

6th out of 9 stocks

AMED stock logo

About Amedisys (NASDAQ:AMED) Stock

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Stock News Headlines

6 Analysts Have This to Say About Amedisys
Amedisys (NASDAQ:AMED) Price Target Cut to $135.00
Amedisys Welcomes Adam Holton as Chief People Officer
Implied QVMM Analyst Target Price: $28 - Nasdaq
Amedisys: Q2 Earnings Snapshot - Greenwich Time
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Company Calendar

Last Earnings
7/27/2022
Today
10/07/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
21,000
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$153.13
High Stock Price Forecast
$213.00
Low Stock Price Forecast
$95.00
Forecasted Upside/Downside
+62.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
15 Analysts

Profitability

Net Income
$209.07 million
Pretax Margin
8.44%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$7.79 per share
Book Value
$29.95 per share

Miscellaneous

Free Float
31,762,000
Market Cap
$3.06 billion
Optionable
Optionable
Beta
1.01

Social Links


Key Executives

  • Mr. Christopher T. GerardMr. Christopher T. Gerard (Age 55)
    CEO, Pres & Director
    Comp: $872.7k
  • Mr. Scott G. GinnMr. Scott G. Ginn (Age 53)
    Exec. VP & CFO
    Comp: $779.31k
  • Mr. David L. KemmerlyMr. David L. Kemmerly (Age 59)
    Chief Legal & Gov. Affairs Officer
    Comp: $547.27k
  • Mr. Pete Hartley
    CTO & Sr. VP of Bus. Operations Systems
  • Mr. Michael P. NorthMr. Michael P. North (Age 57)
    Chief Information Officer
  • Ms. Denise BohnertMs. Denise Bohnert (Age 44)
    Chief Compliance Officer
  • Kendra Kimmons
    VP of Marketing & Communications & Media Relations
  • Ms. Megan Ambers
    Interim Chief HR Officer
  • Mr. John Nugent
    Chief Acquisitions Officer
  • Ms. Janet Britt
    Sr. VP of Billing & Collections













AMED Stock - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 2 sell ratings, 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMED shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price forecast for 2022?

15 brokers have issued 12 month price objectives for Amedisys' shares. Their AMED share price forecasts range from $95.00 to $213.00. On average, they anticipate the company's share price to reach $153.13 in the next year. This suggests a possible upside of 57.6% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2022?

Amedisys' stock was trading at $161.88 at the start of the year. Since then, AMED stock has decreased by 40.0% and is now trading at $97.16.
View the best growth stocks for 2022 here
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our AMED earnings forecast
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) posted its earnings results on Wednesday, July, 27th. The health services provider reported $1.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.24. The health services provider earned $557.89 million during the quarter, compared to analysts' expectations of $583.12 million. Amedisys had a trailing twelve-month return on equity of 17.81% and a net margin of 6.33%. The business's quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter last year, the company posted $1.69 EPS.

How will Amedisys' stock buyback program work?

Amedisys declared that its Board of Directors has authorized a stock repurchase program on Wednesday, August 4th 2021, which permits the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 1.2% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $5.23-$5.45 for the period, compared to the consensus EPS estimate of $5.30. The company issued revenue guidance of $2.29 billion-$2.31 billion, compared to the consensus revenue estimate of $2.35 billion.

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $97.16.

How much money does Amedisys make?

Amedisys (NASDAQ:AMED) has a market capitalization of $3.15 billion and generates $2.21 billion in revenue each year. The health services provider earns $209.07 million in net income (profit) each year or $4.29 on an earnings per share basis.

How many employees does Amedisys have?

The company employs 21,000 workers across the globe.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.

This page (NASDAQ:AMED) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.